{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:23:47Z","timestamp":1787822627809,"version":"build-2784847793"},"reference-count":78,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Myocardial infarction (MI) remains a leading cause of morbidity and mortality despite major advances in reperfusion and secondary prevention. Inflammation contributes throughout the MI continuum, from atherosclerotic plaque development and destabilization to myocardial injury, adverse ventricular remodeling, and recurrent cardiovascular events. Objective: This narrative review summarizes current evidence on inflammation across the MI continuum, focusing on inflammatory biomarkers, cardiovascular imaging, residual inflammatory risk, and emerging anti-inflammatory therapies. Methods: We reviewed current evidence on the pathophysiological and clinical relevance of inflammation in MI, with particular emphasis on circulating biomarkers, multimodality imaging, and inflammation-targeted therapeutic strategies. Results: High-sensitivity C-reactive protein remains the best-established biomarker of residual inflammatory risk, while interleukin-6, myeloperoxidase, suPAR, and GlycA provide complementary information. Advanced imaging, including coronary computed tomography-derived perivascular fat attenuation index, cardiac magnetic resonance, and positron emission tomography, may further characterize vascular and myocardial inflammation. Clinical trials support inflammation as a potentially modifiable component of cardiovascular risk; however, therapeutic benefit has been inconsistent across inflammatory targets, agents, and clinical settings. Canakinumab and low-dose colchicine have demonstrated cardiovascular benefit in selected secondary-prevention populations, although recent neutral trials highlight heterogeneity across clinical settings. Similarly, IL-6-targeted strategies have yielded mixed results, with the neutral ZEUS trial underscoring that biomarker reduction does not necessarily translate into cardiovascular benefit, while NLRP3-targeted approaches remain investigational. Conclusions: Integrating inflammatory biomarkers, multimodality imaging, and targeted therapies may improve risk stratification and support personalized secondary prevention. Further evidence is needed to define optimal patient selection and determine whether biomarker- or imaging-guided anti-inflammatory strategies improve clinical outcomes.<\/jats:p>","DOI":"10.3390\/jcm15176615","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:00:35Z","timestamp":1787821235000},"page":"6615","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Inflammation Across the Myocardial Infarction Continuum: Biomarkers, Imaging, and Emerging Therapies"],"prefix":"10.3390","volume":"15","author":[{"given":"Kristi","family":"Hoxha","sequence":"first","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Maccaferri","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Paparazzo","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1185-1830","authenticated-orcid":false,"given":"Alberto","family":"Sarti","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Sciaramenti","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Camaiti","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1267-5304","authenticated-orcid":false,"given":"Pierpaolo","family":"Cioci","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rizza","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e8","family":"Tezze","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica Rita","family":"Vocale","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Tonet","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-4881","authenticated-orcid":false,"given":"Federico","family":"Marchini","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5150-188X","authenticated-orcid":false,"given":"Gianluca","family":"Campo","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1763-9711","authenticated-orcid":false,"given":"Rita","family":"Pavasini","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/S0140-6736(18)32335-3","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Kyu","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/eurheartj\/ehab892","article-title":"European Society of Cardiology: Cardiovascular disease statistics 2021","volume":"43","author":"Timmis","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"Stark","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.immuni.2019.03.003","article-title":"The Coagulation and Immune Systems Are Directly Linked through the Activation of Interleukin-1\u03b1 by Thrombin","volume":"50","author":"Burzynski","year":"2019","journal-title":"Immunity"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2017-06-780882","article-title":"Inflammation: A key regulator of hematopoietic stem cell fate in health and disease","volume":"130","author":"Pietras","year":"2017","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/eurheartj\/ehad486","article-title":"Inflammation in acute myocardial infarction: The good, the bad and the ugly","volume":"45","author":"Matter","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: A collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, Atherosclerosis, and Coronary Artery Disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1126\/science.1990440","article-title":"Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule During Atherogenesis","volume":"251","author":"Cybulsky","year":"1991","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cell.2011.04.005","article-title":"Macrophages in the Pathogenesis of Atherosclerosis","volume":"145","author":"Moore","year":"2011","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11926-012-0313-z","article-title":"Cholesterol Crystals and Inflammation","volume":"15","author":"Grebe","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"C13","DOI":"10.1016\/j.jacc.2005.10.065","article-title":"Pathology of the Vulnerable Plaque","volume":"47","author":"Virmani","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","first-page":"2984","article-title":"Requiem for the \u2018vulnerable plaque\u2019","volume":"36","author":"Libby","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1093\/eurheartj\/ehaf1059","article-title":"Sex and gender differences in coronary pathophysiology and ischaemic heart disease","volume":"47","author":"Manfrini","year":"2026","journal-title":"Eur. Heart J."},{"key":"ref_18","first-page":"106921","article-title":"Ischemic heart disease and cardioprotection: Focus on estrogenic hormonal setting and microvascular health","volume":"144","author":"Pagliaro","year":"2022","journal-title":"Vasc. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tcm.2025.07.007","article-title":"Gender and Sex-related differences in Type 2 Myocardial Infarction: The undervalued side of a neglected disease","volume":"36","author":"Angeli","year":"2026","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","article-title":"The inflammatory response in myocardial injury, repair, and remodelling","volume":"11","author":"Frangogiannis","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"155848","DOI":"10.1016\/j.cyto.2022.155848","article-title":"Prognostic role of inflammatory cytokines and novel adipokines in acute myocardial infarction: An updated and comprehensive review","volume":"153","author":"Mitsis","year":"2022","journal-title":"Cytokine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00011-024-01916-2","article-title":"The emerging role of fibrin(ogen) in cardiovascular disease","volume":"73","author":"Lan","year":"2024","journal-title":"Inflamm. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/01.ATV.0000163262.83456.6d","article-title":"Myeloperoxidase and Cardiovascular Disease","volume":"25","author":"Nicholls","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12967-017-1321-6","article-title":"GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk","volume":"15","author":"Connelly","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e001118","DOI":"10.1161\/JAHA.114.001118","article-title":"Soluble Urokinase Plasminogen Activator Receptor Level Is an Independent Predictor of the Presence and Severity of Coronary Artery Disease and of Future Adverse Events","volume":"3","author":"Eapen","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in Acute Myocardial Infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_28","unstructured":"Novo Nordisk (2026, August 19). Novo Nordisk Provides Update on the ZEUS Phase 3 Trial in People with ASCVD, CKD and Inflammation. Available online: https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=916587.com."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1161\/CIRCRESAHA.115.306247","article-title":"Imaging Atherosclerosis","volume":"118","author":"Tarkin","year":"2016","journal-title":"Circ. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrcardio.2014.80","article-title":"PET imaging of inflammation in atherosclerosis","volume":"11","author":"Tarkin","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_31","first-page":"1466","article-title":"[68Ga] Pentixafor-PET\/CT for Imaging of Chemokine Receptor 4 Expression After Myocardial Infarction","volume":"8","author":"Lapa","year":"2015","journal-title":"J. Am. Coll. Cardiol. Cardiovasc. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(13)61754-7","article-title":"18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: A prospective clinical trial","volume":"383","author":"Joshi","year":"2014","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1126\/scitranslmed.aal2658","article-title":"Detecting human coronary inflammation by imaging perivascular fat","volume":"9","author":"Antonopoulos","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(18)31114-0","article-title":"Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): A post-hoc analysis of prospective outcome data","volume":"392","author":"Oikonomou","year":"2018","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jacc.2020.05.078","article-title":"Perivascular Fat Attenuation Index Stratifies Cardiac Risk Associated with High-Risk Plaques in the CRISP-CT Study","volume":"76","author":"Oikonomou","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/eurheartj\/ehz474","article-title":"Imaging residual inflammatory cardiovascular risk","volume":"41","author":"Antoniades","year":"2020","journal-title":"Eur. Hear. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jacc.2014.06.1194","article-title":"Comprehensive Prognosis Assessment by CMR Imaging After ST-Segment Elevation Myocardial Infarction","volume":"64","author":"Eitel","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.jacc.2010.01.049","article-title":"Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction","volume":"55","author":"Eitel","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_40","first-page":"569","article-title":"Myocardium at risk after acute infarction in humans on cardiac magnetic resonance: Quantitative assessment during follow-up and validation with single-photon emission computed tomography","volume":"2","author":"Carlsson","year":"2009","journal-title":"J. Am. Coll. Cardiol. Cardiovasc. Imaging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jacc.2011.09.079","article-title":"Consensus Standards for Acquisition, Measurement, and Reporting of Intravascular Optical Coherence Tomography Studies","volume":"59","author":"Tearney","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8584","DOI":"10.1038\/s41598-026-39691-1","article-title":"Residual inflammatory risk and clinical outcomes after contemporary percutaneous coronary intervention: A systematic review and meta-analysis","volume":"16","author":"Romeo","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCRESAHA.116.310527","article-title":"How Common Is Residual Inflammatory Risk?","volume":"120","author":"Ridker","year":"2017","journal-title":"Circ. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-Reactive Protein Levels and Outcomes after Statin Therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"13855","DOI":"10.2147\/JIR.S547594","article-title":"Significance of Residual Inflammatory Risk and Persistent Inflammation in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries","volume":"18","author":"Gao","year":"2025","journal-title":"J. Inflamm. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.tcm.2015.12.001","article-title":"Tissue factor as a link between inflammation and coagulation","volume":"26","author":"Witkowski","year":"2016","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Bo, Y., and Zhao, F. (2025). Platelets as central hubs of inflammation. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1683553"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Masuda, J., Wada, H., Kato, T., Tanigaito, Y., Hayashi, K., Yamada, K., Nishida, K., Oizumi, H., Kamon, T., and Ohkubo, T. (2024). Enhanced Hypercoagulability Using Clot Waveform Analysis in Patients with Acute Myocardial Infarction and Acute Cerebral Infarction. J. Clin. Med., 13.","DOI":"10.3390\/jcm13237181"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehad088","article-title":"Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction","volume":"44","author":"Lee","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A Prospective Natural-History Study of Coronary Atherosclerosis","volume":"364","author":"Stone","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1161\/CIRCULATIONAHA.117.029870","article-title":"Acute Coronary Syndromes: The Way Forward from Mechanisms to Precision Treatment","volume":"136","author":"Crea","year":"2017","journal-title":"Circulation"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in Patients with Chronic Coronary Disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in Patients with Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jamacardio.2023.5155","article-title":"Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial","volume":"9","author":"Nicholls","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/dom.15586","article-title":"The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: A meta-analysis of randomized controlled trials","volume":"26","author":"Buttice","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/dom.14399","article-title":"Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-Dose Methotrexate for the Prevention of Atherosclerotic Events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: A double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized Trial of Interleukin-6 Receptor Inhibition in Patients with Acute ST-Segment Elevation Myocardial Infarction","volume":"77","author":"Broch","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.jacc.2026.01.019","article-title":"Effect of Tocilizumab on Pro\u2013B-Type Natriuretic Peptide and Infarct Size in Patients with Acute Myocardial Infarction at Risk of Cardiogenic Shock (DOBERMANN-T)","volume":"87","author":"Kunkel","year":"2026","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"ref_70","unstructured":"(2026, August 19). ClinicalTrials.gov. A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People with a Heart Attack (ARTEMIS). ClinicalTrials.gov Identifier: NCT06118281, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06118281."},{"key":"ref_71","unstructured":"(2026, August 19). ClinicalTrials.gov. HERMES: Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation. ClinicalTrials.gov Identifier: NCT05636176, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05636176."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41569-023-00946-3","article-title":"The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases","volume":"21","author":"Toldo","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Pagliaro, P., and Penna, C. (2023). Inhibitors of NLRP3 Inflammasome in Ischemic Heart Disease: Focus on Functional and Redox Aspects. Antioxidants, 12.","DOI":"10.3390\/antiox12071396"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/cvr\/cvy145","article-title":"Immunomodulatory interventions in myocardial infarction and heart failure: A systematic review of clinical trials and meta-analysis of IL-1 inhibition","volume":"114","author":"Panahi","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Gong, X., Zhou, C., and Wu, Y. (2026). Persistent residual inflammatory risk at 1 month after contemporary PCI: Rationale for routine hsCRP reassessment and dual-target therapy. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1840386"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Liu, M., Mao, J., Wang, X., Wang, K., and Wang, H. (2026). The systemic immune-inflammation index in coronary heart disease: A narrative review of thromboinflammation, phenotype-dependent utility, and clinical translation. Front. Cardiovasc. Med., 13.","DOI":"10.3389\/fcvm.2026.1778315"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Pathangey, G., Allam, M.N., Abdelnabi, M.H., Sorajja, D., Fortuin, F.D., Lee, K.S., and Bhakta, M.D. (2025). Beyond Lipids and Platelets: A Review of Anti-Inflammatory Strategies in Secondary Prevention of Acute Coronary Syndromes. J. Clin. Med., 14.","DOI":"10.3390\/jcm14227910"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/ATVBAHA.124.319980","article-title":"Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases","volume":"44","author":"Potere","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6615\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:13:32Z","timestamp":1787822012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":78,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176615"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176615","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}